Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence through various resources like daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] - The Momentum Score helps investors capitalize on price trends by evaluating short-term price changes and earnings estimate shifts [5] - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum, serving as a useful indicator alongside the Zacks Rank [6] Zacks Rank and Style Scores Integration - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.64% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated as 1 or 2, making it essential for investors to utilize Style Scores to narrow down their choices [8] - To optimize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering the direction of earnings estimate revisions [9][10] Company Spotlight: Qorvo Inc. - Qorvo Inc. is recognized for its core technologies and RF solutions across mobile, infrastructure, and aerospace/defense sectors [11] - Currently rated 3 (Hold) with a VGM Score of B, Qorvo has a Value Style Score of B, supported by a forward P/E ratio of 15.4, indicating potential interest for value investors [11] - In the past 60 days, seven analysts have raised their earnings estimates for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.51 to $6.06 per share, and an average earnings surprise of +31.2% [12]

Core Insights - Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI) are highlighted as strong buy stocks due to rising earnings estimate revisions and their respective market positions in the medical sector [1][2]. Collegium Pharmaceutical (COLL) - Collegium is recognized as an undervalued specialty pharmaceutical company focusing on central nervous system, respiratory, and skin-related disorders [1]. - The company is projected to achieve a 20% increase in revenue and a 9% increase in earnings this year, with low-single digit growth expected for fiscal 2026 [3]. - Collegium's stock is trading at a forward earnings multiple of 5X and a sales multiple of less than 2X, significantly below the S&P 500 averages and the Zacks Medical-Drugs Industry average of 15.5X forward earnings and 3.4X forward sales [4]. - EPS projections for Collegium have risen to over $7 per share, distinguishing it from over 130 smaller-cap pharmaceutical companies that are currently unprofitable [5]. Masimo Corporation (MASI) - Masimo is noted for its non-invasive health monitoring systems, which provide real-time insights into patient physiology [2]. - The company is expected to see a 20% increase in annual earnings for FY25, reaching $5.30 per share, up from $4.40 last year, with a further 7% increase projected for FY26 [7]. - Masimo's stock trades at a forward earnings multiple of 26.5X, slightly above the Zacks Medical-Instruments Industry average of 23.5X, indicating a justified premium due to its growth prospects [7]. Market Context - Both Collegium and Masimo have experienced significant EPS revisions over the last 60 days, making them attractive options for growth and value in a market characterized by high volatility [9].

Core Viewpoint - Ivanhoe Electric's shares experienced a significant increase of 7.9% to close at $10.84, driven by strong trading volume and higher copper prices [1][2]. Group 1: Company Performance - Ivanhoe Electric is projected to report a quarterly loss of $0.21 per share, reflecting a year-over-year increase of 41.7%. Revenue is expected to reach $1.07 million, marking a 59.7% increase from the same quarter last year [3]. - The consensus EPS estimate for Ivanhoe Electric has remained stable over the past 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [4]. Group 2: Industry Context - The rise in Ivanhoe Electric's stock is attributed to higher copper prices, which increased by 3.77% to $4.84 per pound, following Freeport-McMoRan's declaration of force majeure at its Grasberg mine in Indonesia [2]. - Freeport-McMoRan anticipates a 4% reduction in third-quarter 2025 copper sales and a 6% decrease in gold sales due to operational disruptions [2]. - Hudbay Minerals has also temporarily suspended operations at its Constancia mine in Peru due to protests, raising supply concerns and further supporting price increases [2]. Group 3: Industry Comparisons - Ivanhoe Electric is part of the Zacks Mining - Miscellaneous industry, where Nexa Resources S.A. also operates. Nexa's shares increased by 1.2% to $5.04, with a 1.8% return over the past month [5]. - Nexa Resources' consensus EPS estimate has risen by 25% over the past month to $0.1, representing a 400% increase compared to the previous year's EPS [6].

Core Viewpoint - Southern Copper (SCCO) shares experienced an 8.4% increase, attributed to rising copper prices and significant trading volume [1][2]. Company Performance - Southern Copper is expected to report quarterly earnings of $1.11 per share, reflecting a year-over-year decline of 3.5%, while revenues are projected to be $3.09 billion, marking a 5.3% increase from the previous year [3]. - The consensus EPS estimate for Southern Copper has been revised 11.1% higher in the last 30 days, indicating a positive trend that may lead to further price appreciation [4]. Industry Context - The rise in Southern Copper's stock is linked to higher copper prices, which surged 3.77% to $4.84 per pound due to Freeport-McMoRan Inc. declaring force majeure at its Grasberg mine, impacting supply [2]. - Other companies in the non-ferrous mining industry, such as Energy Fuels, also showed positive stock performance, with Energy Fuels closing 1.2% higher [5].

Financial Performance - CarMax reported quarterly earnings of $0.64 per share, missing the Zacks Consensus Estimate of $1.03 per share, and down from $0.85 per share a year ago, representing an earnings surprise of -37.86% [1] - The company posted revenues of $6.59 billion for the quarter ended August 2025, missing the Zacks Consensus Estimate by 6.52%, and down from $7.01 billion year-over-year [2] - Over the last four quarters, CarMax has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - CarMax shares have lost about 30.2% since the beginning of the year, while the S&P 500 has gained 12.9% [3] - The current Zacks Rank for CarMax is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.82 on revenues of $6.41 billion, and for the current fiscal year, it is $3.89 on revenues of $27.18 billion [7] - The outlook for the Automotive - Retail and Wholesale - Parts industry, where CarMax operates, is currently in the bottom 25% of Zacks industries, which may impact stock performance [8]

Core Viewpoint - Apollo Global Management Inc. (APO) has reached a significant support level and shows potential for investors from a technical perspective, having recently broken through the 200-day moving average, indicating a long-term bullish trend [1]. Technical Analysis - The 200-day simple moving average is a widely-used indicator that helps establish market trends for various financial instruments over the long term, serving as a support or resistance level [2]. - APO has experienced a rally of 7.8% over the past four weeks, and currently holds a Zacks Rank of 3 (Hold), suggesting it may be on the verge of another upward movement [2]. Earnings Estimates - The bullish outlook for APO is further supported by positive earnings estimate revisions, with 7 upward revisions compared to none lower for the current fiscal year, and the consensus estimate has also increased [3]. - The combination of favorable earnings estimate revisions and the achievement of a key technical level positions APO as a stock to watch for potential gains in the near future [3].

Core Viewpoint - Strategy (MSTR) has experienced a decline of -6.7% over the past month, underperforming the Zacks S&P 500 composite's +3.1% and the Zacks Financial - Miscellaneous Services industry's +2.9% [1] Earnings Estimate Revisions - The consensus earnings estimate for Strategy is a loss of $0.11 per share for the current quarter, reflecting a year-over-year change of +93% [4] - The consensus earnings estimate for the current fiscal year is -$15.73, indicating a year-over-year change of -134.1% [4] - For the next fiscal year, the consensus earnings estimate is $0.4, representing a change of +97.5% from the previous year [5] - The Zacks Rank for Strategy is 4 (Sell), indicating a potential underperformance in the near term due to recent changes in earnings estimates [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $118.2 million, showing a year-over-year change of +1.8% [9] - The sales estimates for the current and next fiscal years are $466.75 million and $485.05 million, indicating changes of +0.7% and +3.9%, respectively [9] Last Reported Results and Surprise History - Strategy reported revenues of $114.49 million in the last quarter, a year-over-year increase of +2.7% [10] - The EPS for the same period was $32.6, compared to -$0.76 a year ago, with a surprise of +27266.67% [10] - Over the last four quarters, the company surpassed EPS estimates only once and topped consensus revenue estimates just once [11] Valuation - Strategy is graded F on the Zacks Value Style Score, indicating it is trading at a premium to its peers [15]

Company Overview - Almonty Industries Inc. (ALM) shares increased by 12.3% to close at $5.95, with a notable trading volume compared to typical sessions, and a total gain of 23.5% over the past four weeks [1][2] Project Development - The company has initiated a large-scale drilling program at its Sangdong Molybdenum Project in South Korea, planning to drill 26 holes over 11,700 meters to confirm molybdenum reserves [2][3] - Almonty holds an exclusive agreement to supply 100% of future molybdenum output from the Sangdong project to SeAH M&S, a subsidiary of the SeAH Group, in response to a molybdenum shortage in South Korea [3] Financial Performance - The upcoming quarterly earnings report is expected to show earnings of $0.00 per share, reflecting a year-over-year change of +100%, with revenues projected at $17.33 million, a 248% increase from the previous year [4] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not continue without trends in earnings estimate revisions [5] Industry Context - Almonty Industries is part of the Zacks Mining - Miscellaneous industry, where Teck Resources Ltd (TECK) also operates, having closed at $38.62 with a 0.3% decrease in the last trading session and a 16.3% return over the past month [6]

Company Overview - Alvotech (ALVO) shares increased by 8.6% to close at $8.7, following a notable trading volume that exceeded typical levels, contrasting with a 3.7% loss over the past four weeks [1] - The recent rally is driven by optimism after the EMA's CHMP supported Alvotech's regulatory filings for biosimilar versions of Amgen's Prolia/Xgeva and J&J's Simponi [1] Earnings Expectations - Alvotech is projected to report quarterly earnings of $0.08 per share, reflecting a year-over-year decline of 57.9%, while revenues are expected to reach $114.27 million, marking an 11% increase from the previous year [2] - The consensus EPS estimate for Alvotech has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - Alvotech operates within the Zacks Medical - Biomedical and Genetics industry, where Cytek Biosciences, Inc. (CTKB) also competes, having closed 3.9% lower at $3.71 and showing a -6.1% return over the past month [3] - Cytek Biosciences has a consensus EPS estimate of $0.01 for its upcoming report, unchanged from the previous year, and also holds a Zacks Rank of 3 (Hold) [4]

Company Performance - AAR reported quarterly earnings of $1.08 per share, exceeding the Zacks Consensus Estimate of $0.98 per share, and up from $0.85 per share a year ago, representing an earnings surprise of +10.20% [1] - The company posted revenues of $739.6 million for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 7.86%, compared to $661.7 million in the same quarter last year [2] - AAR has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] Stock Performance - AAR shares have increased approximately 25.5% since the beginning of the year, outperforming the S&P 500's gain of 13.8% [3] - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $706.94 million, and for the current fiscal year, it is $4.43 on revenues of $2.87 billion [7] Industry Outlook - The Aerospace - Defense Equipment industry, to which AAR belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AAR's stock performance [5]